|
5 Companies |
|
7 Products |
|
7 Products |
|
10 Mechanisms of Action |
|
0 Trials |
|
17 News |
|
- | atorvastatin / Generic mfg.
Trial completion, Enrollment change: Modulation of Monocyte Activation by Atorvastatin in HIV Infection (clinicaltrials.gov) - Dec 12, 2017
P4, N=5, Completed, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed | N=15 --> 5
- | Trial completion, Trial primary completion date: Ferumoxytol-enhanced Imaging and Mapping in neuroAIDS (clinicaltrials.gov) - Oct 27, 2017
P2, N=30, Completed, Sponsor: Beau Nakamoto
Active, not recruiting --> Completed | N=15 --> 5 Recruiting --> Completed | Trial primary completion date: Apr 2017 --> Sep 2017
- Tybost (cobicistat) / Gilead
Enrollment change, Trial termination, Trial primary completion date: Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals (clinicaltrials.gov) - Feb 2, 2017
P4, N=7, Terminated, Sponsor: University Hospital, Basel, Switzerland
Recruiting --> Completed | Trial primary completion date: Apr 2017 --> Sep 2017 N=26 --> 7 | Recruiting --> Terminated | Trial primary completion date: Jul 2017 --> Jan 2017; No additional patients fulfilling the inclusion criteria
- atorvastatin / Generic mfg.
Trial primary completion date: Modulation of Monocyte Activation by Atorvastatin in HIV Infection (clinicaltrials.gov) - Jan 17, 2017
P4, N=15, Active, not recruiting, Sponsor: University of Pennsylvania
N=26 --> 7 | Recruiting --> Terminated | Trial primary completion date: Jul 2017 --> Jan 2017; No additional patients fulfilling the inclusion criteria Trial primary completion date: Oct 2016 --> Oct 2017
- atorvastatin / Generic mfg.
Trial primary completion date: Modulation of Monocyte Activation by Atorvastatin in HIV Infection (clinicaltrials.gov) - Aug 22, 2016
P4, N=15, Active, not recruiting, Sponsor: University of Pennsylvania
Trial primary completion date: Oct 2016 --> Oct 2017 Trial primary completion date: Dec 2015 --> Oct 2016
- New P2 trial: Ferumoxytol-enhanced Imaging and Mapping in neuroAIDS (clinicaltrials.gov) - Feb 10, 2016
P2, N=30, Recruiting, Sponsor: Beau Nakamoto
- Tybost (cobicistat) / Gilead
New P4 trial: Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals (clinicaltrials.gov) - Jul 21, 2015
P4, N=26, Recruiting, Sponsor: University Hospital, Basel, Switzerland
- atorvastatin / Generic mfg.
Trial primary completion date: Modulation of Monocyte Activation by Atorvastatin in HIV Infection (clinicaltrials.gov) - Jul 17, 2015
P4, N=15, Active, not recruiting, Sponsor: University of Pennsylvania
Trial primary completion date: Dec 2015 --> Oct 2016 Trial primary completion date: Jun 2014 --> Dec 2015
- Trial completion, Enrollment change: HIV-1 Specific Immune Responses in Thai Individuals With HIV Dementia (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=60, Completed, Sponsor: South East Asia Research Collaboration with Hawaii
Trial primary completion date: Jun 2014 --> Dec 2015 Recruiting --> Completed | N=49 --> 60
- || stavudine / Generic mfg.
Trial completion: A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex (clinicaltrials.gov) - Feb 19, 2014
P3, N=20, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed | N=49 --> 60 No longer recruiting --> Completed
- atorvastatin / Generic mfg.
Enrollment closed: Modulation of Monocyte Activation by Atorvastatin in HIV Infection (clinicaltrials.gov) - Nov 11, 2013
P4, N=15, Active, not recruiting, Sponsor: University of Pennsylvania
No longer recruiting --> Completed Recruiting --> Active, not recruiting
- | Prezista (darunavir) / J&J, Viracept (nelfinavir) / ViiV Healthcare, Roche
Enrollment change: Clinical Trial of CNS-targeted HAART (CIT2) (clinicaltrials.gov) - Nov 8, 2012
P2/3, N=59, Completed, Sponsor: University of California, San Diego
Recruiting --> Active, not recruiting N=120 --> 59
- | Prezista (darunavir) / J&J, Viracept (nelfinavir) / ViiV Healthcare, Roche
Trial completion: Clinical Trial of CNS-targeted HAART (CIT2) (clinicaltrials.gov) - Nov 8, 2012
P2/3, N=59, Completed, Sponsor: University of California, San Diego
N=120 --> 59 Recruiting --> Completed
- Trial completion: The Prevalence of Neurocognitive Disorder in a Primary Care-based HIV Cohort Compared to a HIV-negative Control Cohort - (clinicaltrials.gov) - Oct 21, 2012
P=N/A, N=326, Completed, Sponsor: Holdsworth House Medical Practice
Recruiting --> Completed Recruiting --> Completed
- New P1 trial: Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive Disorders (clinicaltrials.gov) - Aug 13, 2012
P1, N=4, Completed, Sponsor: University of Hawaii
- selegiline / Generic mfg.
Trial completion, Preclinical: A Study of Decreased Mental Function Associated With HIV (clinicaltrials.gov) - Feb 12, 2012
P=N/A, N=90, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Active, not recruiting --> Completed
- atorvastatin / Generic mfg.
Enrollment change: Modulation of Monocyte Activation by Atorvastatin in HIV Infection (clinicaltrials.gov) - Sep 20, 2011
P4, N=15, Active, not recruiting, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed N=20 --> 15